Scientists carrying out coronavirus antibody testing in Scotland are telling Clyde News we still don’t have answers on the big question about immunity.
We’ve been given exclusive access to the lab at Quotient in Penicuik where the tests are done, to find out if our Head of News, Lorraine Herbison, has had COVID-19.
To read the full article and watch the footage, visit: Clyde News
Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.
We are delighted to unveil The L.I.V.E. Xchange, our new showroom and innovation space, at our headquarters in Eysins, Switzerland. The L.I.V.E. Xchange was created to give our customers, development partners, distributors, and other stakeholders access to a dynamic environment
AliveDx and Rowad Medical Services have signed a distribution agreement, which will enable Rowad Medical Services to distribute AliveDx’s products, Alba and MosaiQ®, in the Kingdom of Saudi Arabia. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s
Last week, AliveDx held its first Golden Partners Meeting at its headquarters in Eysins, Switzerland. For four consecutive days, our Golden Partners from all around the world engaged with our management team and representatives from our commercial, regulatory, and technical
We are excited to announce that our abstract on the microarray prototype for the serological detection of eleven IgG autoantibodies commonly found in Connective Tissue Diseases was presented at ACR Convergence 2023, held in San Diego, California. Our poster titled
AliveDx receives three IVDR CE Marks for its automated, multiplexed MosaiQ® solution, enabling faster diagnosis of Connective Tissue Diseases (CTD). Eysins, 24 October 2023 — AliveDx is proud to announce it has received three CE Marks for: Its MosaiQ Centromere
We are thrilled to announce a transformative milestone in our journey—a comprehensive rebranding effort aimed at better reflecting the company’s mission, values, and vision for the future.
